SCHEMBL5230693

SCHEMBL5230693

COc1ccc(CN2C(=O)Cn3cncc3C2c2cccc(Br)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.43
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HSD17B10 Q99714 1/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
GAA P10253 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
RORC P51449 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
LMNA P02545 1/20 0.37
NPBWR1 P48145 1/20 0.37
IDO1 P14902 1/20 0.37
PDE1B Q01064 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5235481 0.92 CYP3A4 (0.44) ALDH1A1POLBCYP3A4CYP2C9CYP2C19
SCHEMBL5225823 0.89 TDP1 (0.42) ALDH1A1POLBMEN1KMT2ARORC
SCHEMBL5229577 0.88 RORC (0.37) ALDH1A1MEN1KMT2ANPSR1HCRTR1
SCHEMBL5231254 0.87 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AGAANPSR1
SCHEMBL5232887 0.85 FNTA (0.38) ALDH1A1CYP3A4HCRTR1HCRTR2RORC
SCHEMBL5231236 0.85 RORC (0.43) ALDH1A1CYP1A2POLBCYP3A4CYP2C19
SCHEMBL5228567 0.83 ALDH1A1 (0.48) ALDH1A1POLBKMT2ANPBWR1
SCHEMBL5228122 0.83 RORC (0.43) ALDH1A1MEN1KMT2ARORC
SCHEMBL5227334 0.81 TP53 (0.41) ALDH1A1MEN1KMT2ANPSR1TDP1
SCHEMBL5230579 0.81 TP53 (0.39) ALDH1A1MEN1KMT2ANPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537114-B8 ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS NOVARTIS AG (CH) 2007-10-03 EP claimed
EP-1537114-A1 ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS Novartis AG (CH) 2005-06-08 EP claimed
WO-2004014914-A1 ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS NOVARTIS AG (CH) 2004-02-19 WO claimed